Product name: pJAK2(1001–1013)

Sequence: LPQDKE(pY)YKVKEP

Modifications:
phosphorylation of Y(7),

Purity: 95% by HPLC

Counter ion: Trifluoroacetate

Format: Lyophilized powder

Description: SOCS1 antagonist pJAK2(1001-1013) peptide upregulated the expression of the maturation marker (CD83) and costimulatory molecule (CD86) of RNA-electroporated human monocyte-derived mature DCs (mDCs), potentiated the capacity of mDCs to induce T-cell proliferation, stimulated the secretion of proinflammatory cytokines, and enhanced the cytotoxicity of tumor cell antigen-specific CTLs activated by human gastric cancer cell total RNA-electroporated mDCs. Data from Western blot analysis indicate that STAT1 was further activated in pJAK2(1001-1013) peptide-loaded mDCs. These results imply that the SOCS1 antagonist pJAK2(1001-1013) peptide is an effective reagent for the enhancement of antigen-specific antitumor immunity by DCs. pJAK2(1001-1013) is able to bind to the KIR region of SOCS-3, similar to its ability to bind to the KIR region of SOCS-1 (manuscript in preparation). Thus, pJAK2(1001-1013) should be effective as an antagonist of SOCS-3. The implication of this is that SOCS antagonists such as pJAK2(1001-1013) potentially possess broad antiviral activity, which would not be the case for siRNA in terms of specificity and possibly issues of practicality of use as an antiviral drug.

Usage: For Scientific Research Use Only, Not for Human Use.

Reference:

Front Immunol. 2015; 6: 183.

Clin Vaccine Immunol. 2013 Sep;20(9):1449-56.

J Immunol. 2010 Jul 15;185(2):1103-13.

J Immunol. 2009 Jul 15;183(2):1253-62.

J Immunol. 2007 Apr 15;178(8):5058-68.

EMBO J. 1999 Mar 1; 18(5):1309-20.